References
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin [Internet]. 2016;66(1):7–30.
- Mahmood U, Levy LB, Nguyen PL, et al. Current clinical presentation and treatment of localized prostate cancer in the United States. J Urol [Internet]. 2014;192(6):1650–1656. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0022534714037677.
- Moul JW. Prostate specific antigen only progression of prostate cancer. J Urol [Internet]. 2000;163(6):1632–1642. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10799151.
- Stephenson AJ, Scardino PT, Eastham JA, et al. Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. JNCI J Natl Cancer Inst [Internet]. 2006;98(10):715–717. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16705126
- Cookson MS, Aus G, Burnett AL, et al. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report. J Urol [Internet]. 2017:177920:540-545. [cited 2017 Jan 30]. Available from http://www.sciencedirect.com/science/article/pii/S0022534706028576.
- Pound CR, Partin AW, Epstein JI, et al. Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control. Urol Clin North Am [Internet]. 1997;24(2):395–406. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9126237.
- Patel A, Dorey F, Franklin J, et al. Recurrence patterns after radical retropubic prostatectomy: clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen. J Urol Internet. 1997;158(4):1441–1445. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9302139.
- Roberts SG, Blute ML, Bergstralh EJ, et al. Time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer. Mayo Clin Proc Internet. 2001;76(6):576–581. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11393495.
- Jarosek SL, Virnig BA, Chu H, et al. Propensity-weighted long-term risk of urinary adverse events after prostate cancer surgery, radiation, or both. Eur Urol. 2015;67(2):273–280.
- Trock BJ, Han M, Freedland SJ, et al. Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA Internet. 2008;299(23):2760–2769. Available from: http://jama.jamanetwork.com/article.aspx?doi=10.1001/jama.299.23.2760
- Jereczek-Fossa BA, Zerini D, Vavassori A, et al. Sooner or later? Outcome analysis of 431 prostate cancer patients treated with postoperative or salvage radiotherapy. Int J Radiat Oncol Internet. 2009;74(1):115–125. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19004572
- Pearse M, Fraser-Browne C, Davis ID, et al. A phase III trial to investigate the timing of radiotherapy for prostate cancer with high-risk features: background and rationale of the Radiotherapy-Adjuvant Versus Early Salvage (RAVES) trial. BJU Int Internet. 2014;113:7–12. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24894850
- Swanson GP, Hussey MA, Tangen CM, et al. Predominant treatment failure in postprostatectomy patients is local: analysis of patterns of treatment failure in SWOG 8794. J Clin Oncol Internet. 2007;25(16):2225–2229. Available from: http://www.jco.org/cgi/doi/10.1200/JCO.2006.09.6495
- Bill-Axelson A, Holmberg L, Ruutu M, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med [Internet]. 2005;352(19):1977–1984. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15888698
- Stephenson AJ, Scardino PT, Kattan MW, et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol Internet. 2007;25(15):2035–2041. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17513807
- Stephenson AJ, Shariat SF, Zelefsky MJ, et al. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA Internet. 2004;291(11):1325–1332. Available from: http://jama.jamanetwork.com/article.aspx?doi=10.1001/jama.291.11.1325
- Stephenson AJ, Slawin KM. The value of radiotherapy in treating recurrent prostate cancer after radical prostatectomy. Nat Clin Pract Urol Internet. 2004;1(2):90–96. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16474521.
- Katz MS, Zelefsky MJ, Venkatraman ES, et al. Predictors of biochemical outcome with salvage conformal radiotherapy after radical prostatectomy for prostate cancer. J Clin Oncol Internet. 2003;21(3):483–489. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12560439.
- Thompson IM, Tangen CM, Paradelo J, et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol [Internet]. 2009;181(3):956–962. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19167731
- Bolla M, van Poppel H, Collette L, et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet Internet. 2005;366(9485):572–578. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16099293
- Wiegel T, Bottke D, Steiner U, et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pt3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol Internet. 2009;27(18):2924–2930. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19433689
- Berry DA, Cronin KA, Plevritis SK, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med Internet. 2005;353(17):1784–1792. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16251534
- Krook JE, Moertel CG, Gunderson LL, et al. Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med Internet. 1991;324(11):709–715. Available from: http://www.ncbi.nlm.nih.gov/pubmed/1997835
- Trabulsi EJ, Valicenti RK, Hanlon AL, et al. A multi-institutional matched-control analysis of adjuvant and salvage postoperative radiation therapy for pT3-4N0 prostate cancer. Urology [Internet]. 2008;72(6):1298–1302. Available from: http://linkinghub.elsevier.com/retrieve/pii/S009042950800770X
- Thomas CT, Bradshaw PT, Pollock BH, et al. Indium-111-capromab pendetide radioimmunoscintigraphy and prognosis for durable biochemical response to salvage radiation therapy in men after failed prostatectomy. J Clin Oncol Internet. 2003;21(9):1715–1721. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12721246
- Valicenti RK, Gomella LG, Ismail M, et al. The efficacy of early adjuvant radiation therapy for pT3N0 prostate cancer: a matched-pair analysis. Int J Radiat Oncol Biol Phys Internet. 1999;45(1):53–58. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10477006
- Thompson IM, Tangen CM, Paradelo J, et al. Adjuvant radiotherapy for pathologically advanced prostate cancer. JAMA Internet. 2006;296(19):2329. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17105795
- Bolla M, van Poppel H, Tombal B, et al. Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). Lancet (London, England) [Internet]. 2012;380(9858):2018–2027. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0140673612612537
- Gandaglia G, Cozzarini C, Mottrie A, et al. The role of radiotherapy after radical prostatectomy in patients with prostate cancer. Curr Oncol Rep Internet. 2015;17(12):53. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26449841
- Van der Kwast TH, Bolla M, Van Poppel H, et al. Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy: EORTC 22911. J Clin Oncol Internet. 2007;25(27):4178–4186. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17878474
- Fossati N, Karnes RJ, Boorjian SA, et al. Long-term impact of adjuvant versus early salvage radiation therapy in pT3N0 prostate cancer patients treated with radical prostatectomy: results from a multi-institutional series. Eur Urol Internet. 2017;71(6):886–893. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27484843
- Fossati N, Karnes RJ, Colicchia M, et al. Impact of early salvage radiation therapy in patients with persistently elevated or rising prostate-specific antigen after radical prostatectomy. Eur Urol Internet. 2017. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28779974
- Briganti A, Wiegel T, Joniau S, et al. Early salvage radiation therapy does not compromise cancer control in patients with pT3N0 prostate cancer after radical prostatectomy: results of a match-controlled multi-institutional analysis. Eur Urol Internet. 2012;62(3):472–487. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0302283812005325
- Parker CC, Sydes MR. Postoperative radiotherapy after radical prostatectomy: let’s work together to tackle the known unknowns. Eur Urol Internet. 2014;65(6):1044–1045. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24103544.
- Cox JD, Gallagher M, Hammond E, et al. Consensus statements on radiation therapy of prostate cancer: guidelines for prostate re-biopsy after radiation and for radiation therapy with rising prostate-specific antigen levels after radical prostatectomy. J Clin Oncol. 1999;17(4):1155–1163.
- Briganti A, Karnes RJ, Joniau S, et al. Prediction of outcome following early salvage radiotherapy among patients with biochemical recurrence after radical prostatectomy. Eur Urol Internet. 2014;66(3):479–486. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24345725
- D’Amico AV, Chen M-H, Sun L, et al. Adjuvant versus salvage radiation therapy for prostate cancer and the risk of death. BJU Int Internet. 2010;106(11):1618–1622. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20553253
- Pfister D, Bolla M, Briganti A, et al. Early salvage radiotherapy following radical prostatectomy. Eur Urol Internet. 2014;65(6):1034–1043. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23972524
- Tendulkar RD, Agrawal S, Gao T, et al. Contemporary update of a multi-institutional predictive nomogram for salvage radiotherapy after radical prostatectomy. J Clin Oncol [Internet]. 2016;34(30):3648–3654. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27528718
- Freedland SJ, Humphreys EB, Mangold LA, et al. Risk of prostate cancer–specific mortality following biochemical recurrence after radical prostatectomy. JAMA Internet. 2005;294(4):433. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16046649
- Den RB, Yousefi K, Trabulsi EJ, et al. Genomic classifier identifies men with adverse pathology after radical prostatectomy who benefit from adjuvant radiation therapy. J Clin Oncol. 2015;33:944–951.
- Cuzick J, Swanson GP, Fisher G, et al. Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. Lancet Oncol. 2011;12(3):245–255.
- Erho N, Crisan A, Vergara IA, et al. Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy. PLoS One Internet. 2013;8(6):e66855. Available from: http://dx.plos.org/10.1371/journal.pone.0066855
- Wu C-L, Schroeder BE, Ma X-J, et al. Development and validation of a 32-gene prognostic index for prostate cancer progression. Proc Natl Acad Sci U S A Internet. 2013;110(15):6121–6126. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23533275
- Pound CR, Partin AW, Eisenberger MA, et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA Internet. 1999;281(17):1591–1597. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10235151.
- Stephenson AJ, Scardino PT, Eastham JA, et al. Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Clin Oncol Internet. 2005;23(28):7005–7012. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16192588
- Eggener SE, Scardino PT, Walsh PC, et al. Predicting 15-year prostate cancer specific mortality after radical prostatectomy. J Urol Internet. 2011;185(3):869–875. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21239008
- Brenner DJ, Curtis RE, Hall EJ, et al. Second malignancies in prostate carcinoma patients after radiotherapy compared with surgery. Cancer Internet. 2000;88(2):398–406. Available from: http://doi.wiley.com/10.1002/%28SICI%291097-0142%2820000115%2988%3A2%3C398%3A%3AAID-CNCR22%3E3.0.CO%3B2-V.
- Moon K, Stukenborg GJ, Keim J, et al. Cancer incidence after localized therapy for prostate cancer. Cancer Internet. 2006;107(5):991–998. Available from: http://doi.wiley.com/10.1002/cncr.22083.
- Cozzarini C, Fiorino C, Da Pozzo LF, et al. Clinical factors predicting late severe urinary toxicity after postoperative radiotherapy for prostate carcinoma: a single-institute analysis of 742 patients. Int J Radiat Oncol Internet. 2012;82(1):191–199. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21109361
- Shipley WU, Seiferheld W, Lukka HR, et al. Radiation with or without antiandrogen therapy in recurrent prostate cancer. N Engl J Med [Internet]. 2017;376(5):417–428. Available from: http://www.nejm.org/doi/10.1056/NEJMoa1607529
- Parker C, Clarke N, Logue J, et al. RADICALS (Radiotherapy and androgen deprivation in combination after local surgery). Clin Oncol. 2007;19(3):167–171.
- Carri C, Hasbini A, De Laroche G, et al. Interest of short hormonotherapy (HT) associated with radiotherapy (RT) as salvage treatment for biological relapse (BR) after radical prostatectomy (RP): results of the GETUG-AFU 16 phase III randomized trial-NCT00423475. J Clin Oncol [Internet]. 2015;33(15). Available from: http://apps.webofknowledge.com.ccmain.ohionet.org/InboundService.do?UT=WOS%3A000358036901047&IsProductCode=Yes&mode=FullRecord&product=WOS&SID=3DyZM3Q6nsEBMX3PcMc&smartRedirect=yes&SrcApp=literatum&DestFail=http%3A%2F%2Fwww.webofknowledge.com%3FDestApp%3D
- Carrie C, Hasbini A, de Laroche G, et al. Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial. Lancet Oncol Internet. 2016;17(6):747–756. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27160475
- Cozzarini C, Montorsi F, Fiorino C, et al. Need for high radiation dose (≥70 Gy) in early postoperative irradiation after radical prostatectomy: a single-institution analysis of 334 high-risk, node-negative patients. Radiat Oncol Biol [Internet]. 2008:75:966–974. Available from: http://ac.els-cdn.com/S0360301609000054/1-s2.0-S0360301609000054-main.pdf?_tid=7c18bc40-813b-11e7-a905-00000aacb361&acdnat=1502747994_ba6a0091c6d09fe3da95b33ddcba9a4a
- Okotie OT, Aronson WJ, Wieder JA, et al. Predictors of metastatic disease in men with biochemical failure following radical prostatectomy. J Urol Internet. 2004;171(6 Pt 1):2260–2264. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15126798
- Dotan ZA, Bianco FJ, Rabbani F, et al. Pattern of prostate-specific antigen (PSA) failure dictates the probability of a positive bone scan in patients with an increasing PSA after radical prostatectomy. J Clin Oncol Internet. 2005;23(9):1962–1968. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15774789
- Cher ML, Bianco FJ, Lam JS, et al. Limited role of radionuclide bone scintigraphy in patients with prostate specific antigen elevations after radical prostatectomy. J Urol Internet. 1998;160(4):1387–1391. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9751361
- Gomez P, Manoharan M, Kim SS, et al. Radionuclide bone scintigraphy in patients with biochemical recurrence after radical prostatectomy: when is it indicated? BJU Int Internet. 2004;94(3):299–302. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15291855.
- Saleem MD, Sanders H, Abu El Naser M, et al. Factors predicting cancer detection in biopsy of the prostatic fossa after radical prostatectomy. Urology [Internet]. 1998;51(2):283–286. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9495712.
- Scattoni V, Montorsi F, Picchio M, et al. Diagnosis of local recurrence after radical prostatectomy. BJU Int Internet. 2004;93(5):680–688. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15009088
- Koppie TM, Grossfeld GD, Nudell DM, et al. Is anastomotic biopsy necessary before radiotherapy after radical prostatectomy? J Urol Internet. 2001;166(1):111–115. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11435834.
- Miralbell R, Vees H, Lozano J, et al. Endorectal MRI assessment of local relapse after surgery for prostate cancer: a model to define treatment field guidelines for adjuvant radiotherapy in patients at high risk for local failure. Int J Radiat Oncol Internet. 2007;67(2):356–361. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17236961
- Sciarra A, Panebianco V, Salciccia S, et al. Role of dynamic contrast-enhanced magnetic resonance (MR) imaging and proton MR spectroscopic imaging in the detection of local recurrence after radical prostatectomy for prostate cancer. Eur Urol Internet. 2008;54(3):589–600. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18226441
- Amzalag G, Rager O, Tabouret-Viaud C, et al. Target definition in salvage radiotherapy for recurrent prostate cancer: the role of advanced molecular imaging. Front Oncol Internet. 2016;6:73. Available from: http://journal.frontiersin.org/Article/10.3389/fonc.2016.00073/abstract
- Lindenberg ML, Turkbey B, Mena E, et al. Imaging locally advanced, recurrent, and metastatic prostate cancer. JAMA Oncol [Internet]. 2017. [cited 2017 Feb 04]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28097325.
- Fanti S, Minozzi S, Castellucci P, et al. PET/CT with 11C-choline for evaluation of prostate cancer patients with biochemical recurrence: meta-analysis and critical review of available data. Eur J Nucl Med Mol Imaging Internet. 2016;43(1):55–69. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26450693
- Evangelista L, Zattoni F, Guttilla A, et al. Choline PET or PET/CT and biochemical relapse of prostate cancer. Clin Nucl Med Internet. 2013;38(5):305–314. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23486334
- Mohsen B, Giorgio T, Rasoul ZS, et al. Application of 11 C-acetate positron-emission tomography (PET) imaging in prostate cancer: systematic review and meta-analysis of the literature. BJU Int Internet. 2013;112(8):1062–1072. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23937453
- Nanni C, Zanoni L, Pultrone C, et al. 18F-FACBC (anti1-amino-3-18F-fluorocyclobutane-1-carboxylic acid) versus 11C-choline PET/CT in prostate cancer relapse: results of a prospective trial. Eur J Nucl Med Mol Imaging Internet. 2016;43(9):1601–1610. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26960562
- Afshar-Oromieh A, Zechmann CM, Malcher A, et al. Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging Internet. 2014;41(1):11–20. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24072344
- Perera M, Papa N, Christidis D, et al. Sensitivity, specificity, and predictors of positive 68Ga–prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and meta-analysis. Eur Urol Internet. 2016;70(6):926–937. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27363387
- Richaud P, Sargos P, Henriques de Figueiredo B, et al. [Postoperative radiotherapy of prostate cancer]. Cancer Radiother [Internet]. 2010;14(6–7):500–503. Available from: http://linkinghub.elsevier.com/retrieve/pii/S1278321810003562